334 related articles for article (PubMed ID: 19680296)
1. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
Burris HA
Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
3. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
Hirsch FR
Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
[TBL] [Abstract][Full Text] [Related]
4. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
[TBL] [Abstract][Full Text] [Related]
6. Optimizing therapy in previously treated non-small cell lung cancer.
Miller VA
Semin Oncol; 2006 Feb; 33(1 Suppl 1):S25-31. PubMed ID: 16472706
[TBL] [Abstract][Full Text] [Related]
7. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
8. Integrating new targeted agents into the treatment of non-small-cell lung cancer.
Thatcher N
Lung Cancer; 2006 Dec; 54 Suppl 2():S25-31. PubMed ID: 17056150
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.
Araújo A; Ribeiro R; Azevedo I; Coelho A; Soares M; Sousa B; Pinto D; Lopes C; Medeiros R; Scagliotti GV
Oncologist; 2007 Feb; 12(2):201-10. PubMed ID: 17296816
[TBL] [Abstract][Full Text] [Related]
10. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly.
Gridelli C; Massarelli E; Maione P; Rossi A; Herbst RS; Onn A; Ciardiello F
Cancer; 2004 Oct; 101(8):1733-44. PubMed ID: 15386339
[TBL] [Abstract][Full Text] [Related]
11. What phase III trials are needed to improve the treatment of advanced non-small-cell lung cancer?
Saijo N
Nat Clin Pract Oncol; 2005 Jun; 2(6):275. PubMed ID: 16264964
[No Abstract] [Full Text] [Related]
12. Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors.
Kotteas EA; Charpidou AG; Syrigos KN
Anticancer Drugs; 2010 Feb; 21(2):151-68. PubMed ID: 20016368
[TBL] [Abstract][Full Text] [Related]
13. Multitargeted inhibitors in lung cancer: new clinical data.
Bar J; Herbst RS; Onn A
Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
[TBL] [Abstract][Full Text] [Related]
14. Molecular selection for therapy of patients with non-small-cell lung cancer and impaired performance status: has the time come?
Lara PN
Clin Lung Cancer; 2006 Jan; 7(4):232-4. PubMed ID: 16512975
[No Abstract] [Full Text] [Related]
15. Novel agents in the treatment of non-small cell lung cancer: implications for neoadjuvant chemotherapy?
Bergqvist M; Henriksson R; Brattström D
In Vivo; 2005; 19(3):523-33. PubMed ID: 15875771
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies and non-small-cell lung cancer: new developments.
Gridelli C
Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976
[No Abstract] [Full Text] [Related]
17. Targeting novel and established therapies for non-small cell lung cancer.
Spicer J; Chowdhury S; Harper P
Cancer Lett; 2007 May; 250(1):9-16. PubMed ID: 17030089
[TBL] [Abstract][Full Text] [Related]
18. The role of maintenance chemotherapy in advanced nonsmall cell lung cancer.
Jalal SI; Ademuyiwa FO; Hanna NH
Curr Opin Oncol; 2009 Mar; 21(2):110-5. PubMed ID: 19532011
[TBL] [Abstract][Full Text] [Related]
19. New targets for non-small-cell lung cancer therapy.
Alvarez M; Roman E; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
Rigas JR; Dragnev KH
Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
